

**H.R. 7347, a bill to amend title 38, United States Code, to direct the Secretary of Veterans Affairs to report on whether the Secretary will include certain psychedelic drugs in the formulary of the Department of Veterans Affairs**  
As ordered reported by the House Committee on Veterans Affairs on May 1, 2024

By Fiscal Year, Millions of Dollars		2024	2024-2029	2024-2034
Direct Spending (Outlays)		0	0	0
Revenues		0	0	0
Increase or Decrease (-) in the Deficit		0	0	0
Spending Subject to Appropriation (Outlays)		*	*	*
Increases <i>net direct spending</i> in any of the four consecutive 10-year periods beginning in 2035?	No	Statutory pay-as-you-go procedures apply?		No
		Mandate Effects		
	No	Contains intergovernmental mandate?		No
		Contains private-sector mandate?		No
* = between zero and \$500,000.				

H.R. 7347 would require the Department of Veterans Affairs (VA) to report to the Congress whenever a decision is made about whether to include on VA's prescription formulary, psychedelic drugs that have been approved by the Food and Drug Administration.

Under current law, VA publicizes its decisions about what to include in the department's formulary, and to date, no psychedelic drugs have been approved for medical use by the Food and Drug Administration. CBO estimates that satisfying the requirement to report to the Congress would cost less than \$500,000 over the 2024-2034 period.

The CBO staff contact for this estimate is Matt Schmit. The estimate was reviewed by Christina Hawley Anthony, Deputy Director of Budget Analysis.



Phillip L. Swagel  
Director, Congressional Budget Office